Achieve Life Sciences (ACHV) Enterprise Value (2010 - 2026)

Achieve Life Sciences (ACHV) has 17 years of Enterprise Value data on file, last reported at -$30.5 million in Q1 2026.

• Quarterly Enterprise Value fell 31.17% year-over-year to -$30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.5 million (down 31.17% YoY) and the FY2025 annual result came in at -$51.9 million, down 50.97% from the prior year.
• Enterprise Value grew to -$30.5 million in Q1 2026, from -$51.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$14.3 million in Q4 2023 to a low of -$66.4 million in Q1 2024.
• A 5-year average of -$35.9 million and a median of -$30.5 million in 2026 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value sank 302.08% — and 2025, when it jumped 64.99%.
• Tracing ACHV's Enterprise Value over 5 years: stood at -$24.8 million in 2022, then soared by 42.46% to -$14.3 million in 2023, then plunged by 141.09% to -$34.4 million in 2024, then sank by 50.97% to -$51.9 million in 2025, then surged by 41.22% to -$30.5 million in 2026.
• The last three Enterprise Value figures came in at -$30.5 million (Q1 2026), -$51.9 million (Q4 2025), and -$64.3 million (Q3 2025), per Business Quant data.